Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Insulin resistance (IR) contributes to the development of glucose intolerance (post-transplant diabetes mellitus or impaired glucose tolerance) following renal transplantation. Furthermore, endothelial dysfunction (ED) is associated with IR. Glucose intolerance, IR and ED are all independent risk factors for cardiovascular disease. Therefore, treatment with insulin sensitizers may benefit glucose-intolerant renal transplant recipients. The main objectives of the present study were to investigate the effect of 4 weeks' treatment with the PPAR-gamma agonist rosiglitazone on insulin sensitivity, plasma glucose and endothelial function in renal transplant recipients with glucose intolerance. Safety parameters were also addressed. METHODS: A total of 10 glucose-intolerant renal transplant recipients were treated with rosiglitazone (initially 4 mg/day increasing to 8 mg/day after 1 week). A hyperinsulinaemic euglycaemic glucose clamp, an oral glucose tolerance test and endothelial function assessment with laser Doppler flowmetry were performed both at baseline and at follow-up. RESULTS: Treatment with rosiglitazone was followed by a significantly improved mean glucose disposal rate (from 6.5 to 9.1 g/kg/min; P = 0.02) and a significant decline in fasting and 2 h plasma glucose (from 6.4 to 5.8 mmol/l, P = 0.01 and from 14.2 to 10.6 mmol/l, P = 0.03, respectively). Furthermore, a significant improvement in endothelial function was demonstrated (AUC(ACh); from 389 to 832 AU x min, P = 0.04). No serious adverse events or hypoglycaemic episodes were observed. CONCLUSIONS: Four weeks' treatment with rosiglitazone was associated with increased insulin sensitivity, lowered fasting and 2 h plasma glucose and improved endothelial function in renal transplant recipients with glucose intolerance. The drug was well tolerated and may be a good alternative for treating these patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · The Lancet · doi:10.1016/s0140-6736(98)12131-1 · Cited by 1,313
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Cited by
Peroxisome proliferator-activated receptors and inflammation
Moraes, L. A., Piqueras, L., & Bishop-Bailey, D. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.08.007 · Cited by 376
Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia
Sharif, A., Moore, R., & Baboolal, K. (2008) · Transplantation · doi:10.1097/tp.0b013e3181605ebf · Cited by 144
“While some of the new hypoglycemic agents have been studied in renal transplant recipients, such as repaglinide (30) and rosiglitazone (31), the older and more commonly used hypoglycemic agents have not been assessed in this particular population.”
BackgroundEmerging treatments for post-transplantation diabetes mellitus
Jenssen, T., & Hartmann, A. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.59 · Cited by 90
Self-citationStrom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft536 · Cited by 89
Self-citationDiabetes Care After Transplant
Wallia, A., Illuri, V., & Molitch, M. E. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.01.005 · Cited by 50
Metadata
- Authors
- Voytovich, M. H., Simonsen, C., Jenssen, T., Hjelmesaeth, J., Asberg, A., & Hartmann, A.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-12-22
- Volume
- 20
- Issue
- 2
- Pages
- 413-418
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2118007770
- Cited by
- 60
- References
- 2
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. https://app.cochat.ai/papers/10.1093/ndt/gfh641
- The paper
- Voytovich, M. H., Simonsen, C., Jenssen, T., Hjelmesaeth, J., Asberg, A., & Hartmann, A. (2005). Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfh641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.